Valeant Pharmaceuticals International Inc., of Laval, Quebec, said subsidiary Bausch & Lomb and Sophia Antipolis, France-based Nicox SA gained FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024 percent) for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Bausch & Lomb in-licensed the program from Nicox in 2010.